These data suggest that CD8-positive TSCM population among the CAR-T cell products was most significantly associated with an objective and durable response in r/rDLBCL patients treated with CAR-T cell therapy, especially in patients with a heavy tumour burden. The gene discussed is CD8A; the disease is neoplasm.